Beam Therapeutics Inc (BEAM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Beam Therapeutics Inc (BEAM) has a cash flow conversion efficiency ratio of -0.110x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-128.51 Million) by net assets ($1.16 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BEAM equity to assets ratio to measure how much of total assets are equity-financed.
Beam Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Beam Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Beam Therapeutics Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Beam Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beam Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ZIM Integrated Shipping Services Ltd.
F:2SV
|
0.093x |
|
Home Product Center Public Company Limited
BK:HMPRO
|
0.023x |
|
Digi International Inc
NASDAQ:DGII
|
0.063x |
|
First Merchants Corporation
NASDAQ:FRME
|
0.033x |
|
Shenzhen Senior Technology Material Co Ltd
SHE:300568
|
0.012x |
|
Ichor Holdings Ltd
NASDAQ:ICHR
|
-0.004x |
|
Fortuna Silver Mines Inc
TO:FVI
|
0.066x |
|
Ermenegildo Zegna NV
NYSE:ZGN
|
0.111x |
Annual Cash Flow Conversion Efficiency for Beam Therapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Beam Therapeutics Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see BEAM stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.24 Billion | $-345.10 Million | -0.279x | +41.13% |
| 2024-12-31 | $733.54 Million | $-347.25 Million | -0.473x | -211.37% |
| 2023-12-31 | $981.33 Million | $-149.19 Million | -0.152x | -595.02% |
| 2022-12-31 | $733.47 Million | $22.53 Million | 0.031x | +138.32% |
| 2021-12-31 | $826.74 Million | $-66.27 Million | -0.080x | +79.44% |
| 2020-12-31 | $245.56 Million | $-95.74 Million | -0.390x | +45.34% |
| 2019-12-31 | $100.94 Million | $-72.00 Million | -0.713x | -370.99% |
| 2018-12-31 | $134.03 Million | $-20.30 Million | -0.151x | -123.40% |
| 2017-12-31 | $-4.18 Million | $-2.71 Million | 0.647x | -- |
About Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targ… Read more